UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Herceptin: mechanisms of action and resistance

Cancer letters, 2006-02, Vol.232 (2), p.123-138

2006

Volltextzugriff (PDF)

HER2 therapy: molecular mechanisms of trastuzumab resistance

Breast cancer research : BCR, 2006-01, Vol.8 (6), p.215-215, Article 215

2006

Volltextzugriff (PDF)

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

Breast cancer research and treatment, 2012-08, Vol.135 (1), p.39-48

2012

Volltextzugriff (PDF)

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

Cancer research (Chicago, Ill.), 2005-12, Vol.65 (23), p.11118-11128

2005

Volltextzugriff (PDF)

Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

Nature clinical practice. Oncology, 2006-05, Vol.3 (5), p.269-280

2006

Volltextzugriff (PDF)

Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism

Cancer research (Chicago, Ill.), 2011-07, Vol.71 (13), p.4585-4597

2011

Volltextzugriff (PDF)

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells

Cancer research (Chicago, Ill.), 2004-04, Vol.64 (7), p.2343-2346

2004

Volltextzugriff (PDF)

Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies

Breast cancer research and treatment, 2020-10, Vol.183 (3), p.599-606

2020

Volltextzugriff (PDF)

FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells

Oncotarget, 2015-03, Vol.6 (7), p.4757-4772

2015

Volltextzugriff (PDF)

Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling

Oncotarget, 2017-11, Vol.8 (55), p.94393-94406

2017

Volltextzugriff (PDF)

Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion

Biochemical pharmacology, 2013-01, Vol.85 (1), p.46-58

2013

Volltextzugriff (PDF)

Systemic therapy for early‐stage HER2‐positive breast cancers: Time for a less‐is‐more approach?

Cancer, 2015-02, Vol.121 (4), p.517-526

2015

Volltextzugriff (PDF)

Catalytic Deoxyribozyme-Modified Nanoparticles for RNAi-Independent Gene Regulation

ACS nano, 2012-10, Vol.6 (10), p.9150-9157

2012

Volltextzugriff (PDF)

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling

Molecular cancer therapeutics, 2007-02, Vol.6 (2), p.667-674

2007

Volltextzugriff (PDF)

Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell Lines

Breast Cancer: Basic and Clinical Research, 2011-01, Vol.2011 (2011), p.143-154

2011

Volltextzugriff (PDF)

Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells

Biochemical pharmacology, 2011-11, Vol.82 (9), p.1090-1099

2011

Volltextzugriff (PDF)

Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines

Current pharmacogenomics and personalized medicine, 2011-09, Vol.9 (3), p.184-190

2011

Volltextzugriff (PDF)

A Novel Unidirectional Cross-Talk from the Insulin-Like Growth Factor-I Receptor to Leptin Receptor in Human Breast Cancer Cells

Molecular cancer research, 2008-06, Vol.6 (6), p.1052-1058

2008

Volltextzugriff (PDF)

Phosphatase magnesium-dependent 1 δ (PPM1D), serine/threonine protein phosphatase and novel pharmacological target in cancer

Biochemical pharmacology, 2021-02, Vol.184, p.114362-114362, Article 114362

2021

Volltextzugriff (PDF)

Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance

Chemotherapy Research and Practice, 2012-01, Vol.2012 (2012), p.143-149

2012

Volltextzugriff (PDF)

Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer

ISRN oncology, 2012, Vol.2012 (2012), p.1-16

2012

Volltextzugriff (PDF)

Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer

Molecular cancer therapeutics, 2008-07, Vol.7 (7), p.1900-1908

2008

Volltextzugriff (PDF)

Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance

Anti-cancer agents in medicinal chemistry, 2012-02, Vol.12 (2), p.151-162

2012

Volltextzugriff (PDF)

ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer

Expert opinion on biological therapy, 2018-03, Vol.18 (3), p.335-341

2018

Volltextzugriff (PDF)

Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance

Current medicinal chemistry, 2012-03, Vol.19 (7), p.1065-1075

Nahta, R

2012

Volltextzugriff (PDF)

1 – 25 von 85

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Englisch
(85)

Erscheinungsjahr

n.n

Thema

Science & Technology
(57)
Life Sciences & Biomedicine
(56)
Humans
(49)
Oncology
(44)
Female
(34)
Trastuzumab
(32)
Breast Neoplasms - Drug Therapy
(29)
Breast Cancer
(25)
Breast Neoplasms - Metabolism
(20)
Antibodies, Monoclonal, Humanized
(18)
Antineoplastic Agents - Pharmacology
(18)
Biological And Medical Sciences
(17)
Cell Line, Tumor
(17)
Medical Sciences
(17)
Breast Neoplasms - Pathology
(16)
Receptor, Erbb-2 - Metabolism
(16)
Antibodies, Monoclonal - Pharmacology
(14)
Antineoplastic Agents - Therapeutic Use
(14)
Drug Resistance, Neoplasm
(14)
Animals
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Herceptin: mechanisms of action and resistance

HER2 therapy: molecular mechanisms of trastuzumab resistance

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells

Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies

FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells

Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling

Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion

Systemic therapy for early‐stage HER2‐positive breast cancers: Time for a less‐is‐more approach?

Catalytic Deoxyribozyme-Modified Nanoparticles for RNAi-Independent Gene Regulation

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling

Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell Lines

Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells

Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines

A Novel Unidirectional Cross-Talk from the Insulin-Like Growth Factor-I Receptor to Leptin Receptor in Human Breast Cancer Cells

Phosphatase magnesium-dependent 1 δ (PPM1D), serine/threonine protein phosphatase and novel pharmacological target in cancer

Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance

Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer

Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer

Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance

ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer

Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance

Suchergebnisse filtern